Patent application number | Description | Published |
20090117641 | Mutated Abl Kinase Domains - The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides. | 05-07-2009 |
20100021920 | MUTATED ABL KINASE DOMAINS - The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides. | 01-28-2010 |
20100021921 | MUTATED ABL KINASE DOMAINS - The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides. | 01-28-2010 |
Patent application number | Description | Published |
20100282547 | Disc Brake for a Commercial Vehicle - A disc brake for a commercial vehicle has a caliper that straddles a brake disc. The caliper is mounted on a brake carrier on the vehicle side by way of two connecting bearings in an axially displaceable manner in relation to the brake disc. The connecting bearings each include a guide bar that is securely connected to the brake carrier and guided in a slide bearing of the caliper for the axial displacement thereof. At least one connecting bearing is provided with a radially elastic damping bushing, which at least surrounds the guide bar in regions and has grooves that are laterally delimited by ribs. The disc brake is designed such that the damping bushing has a progressive damping behavior in the radial loading direction. | 11-11-2010 |
20120073912 | Pneumatically or Electromechanically Actuated Disc Brake - A pneumatic or electromagnetically actuated disc brake includes a caliper spanning a brake disc, a brake application unit disposed in the caliper and having a brake lever, at least one actuating spindle axially displaceable by the rotary lever, and a wear adjustor actuated by the brake lever and positioned in the brake caliper, by which a wear-induced change in an air gap between a brake pad and the brake disc can be substantially compensated for by way of an axial adjustment of the actuating spindle. The wear adjustor includes a spur gear segment extending in the pivot direction and disposed on the lever and engaging with a crown gear operationally connected to the actuating spindle for adjusting. | 03-29-2012 |
20140345983 | Brake Pad Retention System of a Disc Brake of a Motor Vehicle - A brake pad retention system is provided for a disc brake of a motor vehicle, in particular of a commercial vehicle. The disc brake includes a brake caliper which engages over a brake disc, a brake carrier which is positionally fixed on the vehicle, the brake carrier having entry-side and exit-side carrier horns and having a bridge which connects the carrier horns to one another, and at least one brake pad which is provided with a pad carrier plate and a friction pad fastened thereto and which is guided in a pad shaft formed by the carrier horns and by the bridge. At least one of the carrier horns of the carrier and the support surface, adjacent thereto, of the pad carrier plate can be fixed to one another in a positively locking manner with play. The at least one brake pad is held in the pad shaft under spring loading exerted by a pad retention spring which extends transversely with respect to the axial direction of the brake disc and which is radially deflectable on the brake pad. The at least one pad retention spring is arranged such that the pad retention spring, in the assembled state, presses the brake pad away from the bridge part of the brake carrier and against the carrier horns without play. | 11-27-2014 |
20150184710 | Arrangement of a Pad Retaining Clip on the Brake Caliper of a Disc Brake, and Brake Pad - A disk brake includes a brake caliper and two brake pads, which can be pressed onto a brake disk on both sides and which each have a pad carrier plate and a friction pad fastened thereto. A pad retaining clip, which is retained on the brake caliper and which spans an installation opening, is supported on the brake pads. The pad retaining clip is fastened to a form closure element of at least one brake pad so as to be secured against movement. | 07-02-2015 |
20150192181 | ADJUSTING DEVICE FOR A DISK BRAKE, CORRESPONDING DISK BRAKE AND METHOD FOR OPERATING A WEAR ADJUSTMENT DEVICE FOR A DISK BRAKE - An adjusting device is disclosed for adjusting friction surface wear on brake linings and a brake disk of a disk brake. The adjusting device is couplable to a brake application device on the drive side, and to a spindle unit of the disk brake on the output side. The adjusting device includes a drive element on both sides of which a rolling element assembly is axially arranged; a pressure element; an output element coupled to the pressure element for coupling to a coupling wheel; an energy storage element; and a support body, one end of which is connected to a bearing plate and around which the drive element, the rolling element assemblies, the output element and the energy storage element are arranged axially in series with the bearing plate. The energy storage element is arranged between a bearing portion of the support body and the pressure element. | 07-09-2015 |
Patent application number | Description | Published |
20130224306 | METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION WITHOUT COMPANION DIAGNOSIS - There is provided a method for treating pulmonary hypertension in a subject, comprising: administering to the subject in need thereof a daily dose of ambrisentan from 1 mg to about 15 mg, wherein the method is carried out without drug labeling instruction to monitor liver aminotransferase levels during ambrisentan treatment. | 08-29-2013 |
20130225595 | METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION IN A PATIENT NOT HAVING IDIOPATHIC PULMONARY FIBROSIS - There is provided a method of treating pulmonary hypertension in a patient in need thereof, said method comprising: administering a therapeutically effective amount of ambrisentan to the patient with pulmonary arterial hypertension, wherein the patient has been determined not to have idiopathic pulmonary fibrosis. | 08-29-2013 |
20130225607 | METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION WITHOUT COMPANION DIAGNOSIS - There is provided a method for treating pulmonary hypertension in a subject, comprising: administering to the subject in need thereof a daily dose of ambrisentan from 1 mg to about 15 mg, wherein the method is carried out without drug labeling instruction to monitor liver aminotransferase levels during ambrisentan treatment. | 08-29-2013 |
20140030356 | METHOD FOR TREATING A PULMONARY HYPERTENSION CONDITION WITHOUT COMPANION DIAGNOSIS - There is provided a method for treating pulmonary hypertension in a subject, comprising: administering to the subject in need thereof a daily dose of ambrisentan from 1 mg to about 15 mg, wherein the method is carried out without drug labeling instruction to monitor liver aminotransferase levels during ambrisentan treatment. | 01-30-2014 |
20140275094 | METHOD FOR TREATING PULMONARY ARTERIAL HYPERTENSION IN A PATIENT NOT HAVING IDIOPATHIC PULMONARY FIBROSIS - There is provided a method of treating pulmonary hypertension in a patient in need thereof, said method comprising: administering a therapeutically effective amount of ambrisentan to the patient with pulmonary arterial hypertension, wherein the patient has been determined not to have idiopathic pulmonary fibrosis. | 09-18-2014 |